Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (8161)	1/1/1999 7:45:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Larry, thanks. BW has its industry outlook for 1000 and while nothing really new in the article the intro. to drugs and biotech says, "It just dosn't get any better than this," says one analyst. Also, ""For the biotech industry, 1999 will be a year when the promise of that sector comes closer to reality. " and 21 biotech cos. will be in the black with profits of $2 billion up from $1.5 billion. Article did not say how many are presently in the black. Must say, I read this stuff, with a jaundiced eye. But in the end it is better than everyone saying it will be a bad year for biotech. Just always keep in mind that all the optimistic articles in the world don't mean the performance will be there. I see real problems in raising cash. I think mergers might provide some relief for those that escape predators as a lift in the price of their stock due to merger fever may permit raising capital on better terms. Approvals should help the group as well for much the same reasons. I think we should be close to 575 accruals in the trauma trials, according to my simplistic graph. XOMA with two phase III trials seems well positioned. Of course the results of the meningo trial will prove that true or false. IMO the loneflycater was more on target than sandboots and prof_mentor.